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ScienceDirectCancer immunotherapy aims to augment the response of the
patient’s own immune system against cancer cells. Despite
effective for some patients and some cancer types, the
therapeutic efficacy of this treatment is limited by the
composition of the tumor microenvironment (TME), which is not
well-suited for the fitness of anti-tumoral immune cells.
However, the TME differs between cancer types and tissues,
thus complicating the possibility of the development of
therapies that would be effective in a large range of patients. A
possible scenario is that each type of cancer cell, granted by its
own mutations and reminiscent of the functions of the tissue of
origin, has a specific metabolism that will impinge on the
metabolic composition of the TME, which in turn specifically
affects T cell fitness. Therefore, targeting cancer or T cell
metabolism could increase the efficacy and specificity of
existing immunotherapies, improving disease outcome and
minimizing adverse reactions.
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Introduction
Immunotherapy is a promising treatment option for
patients with different cancers resistant to conventional
therapies. Therapeutic regimens such as adoptive T cell
transfer (ACT), cancer vaccines and immune checkpoint
inhibitors (ICI) (e.g. a-PD-1, a-PDL-1 or a-CTLA-4
antibodies), harness the ability of the immune system
to recognize and reject the tumor [1]. T cells are the major
players in these therapeutic options due to their antigen
specificity, robust killing capacity and longevity. DespiteCurrent Opinion in Biotechnology 2021, 68:124–143 these intrinsic T cell characteristics, immunotherapy has
been largely ineffective for the majority of patients. It is
believed that this low efficacy is due to the highly
immunosuppressive tumor microenvironment (TME)
which limits the infiltration of the invigorated immune
cells delivered by immunotherapy. Cancer cell metabo-
lism contributes greatly to this immunosuppressive envi-
ronment by depleting nutrients and secreting metabolites
that inhibit anti-tumoral effector T cells [2].
Cancer cells are well known for their ability to modulate
their metabolic processes in order to fuel their uncon-
trolled proliferation and create an environment which
prohibits the infiltration of effector T cells while recruit-
ing immunosuppressive cell types such as regulatory T
cells (Treg) or tumor-associated macrophages (TAMs)
[3]. Research suggests that the metabolic reprograming
of cancer cells is one of the major factors responsible for
the development of therapy resistance [4]. Therefore,
targeting metabolic processes of cancer cells and/or T
cells in combination with immunotherapy could boost the
efficacy of this therapeutic option.
An additional parameter to consider when designing
therapeutics targeting cancer-metabolism or immuno-
metabolism is the organ in which the tumor develops.
Different tissues support different cellular functions
which are accompanied by distinct metabolic needs.
An example of tissue with a very specific cellular metab-
olism is the prostate. Epithelial cells in the prostate are
well characterized to produce citrate instead of oxidizing
it in the TCA cycle as it is common in other tissues
(Figure 1) [5]. Furthermore, different oncogenic addic-
tions or oncosuppressive cues (recurrent in some but not
in other tumor histotypes) can rewire the metabolism of
cancer cells towards a specific direction. For example,
copy numbers of oncogenic KRAS mutant in lung cancer
(LC) correlate with augmented glucose uptake and
increased channeling of glucose-derived metabolites into
the TCA cycle [6]. These two considerations lead to the
obvious conclusion that cancer types originating in the
same organ can be characterized by very different meta-
bolic profiles requiring a different treatment approach
(Box 1).
The presence of tumor infiltrating lymphocytes (TILs) in
solid tumors is strongly correlated to improved disease
outcome. T cells represent the major cell type in TILs. Of
those, CD8+T cells most strongly correlate with favorablewww.sciencedirect.com
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Metabolic features in healthy tissue. (a) Metabolism in healthy breast tissue is characterized by low concentrations of intracellular serine, high
production and secretion of the adipokine leptin. Additionally, breast tissue has low amounts of ROS due in part by high antioxidant response. (b)
Melanocytes in healthy skin have a low proliferative rate and metabolism that is dominated by OXPHOS. High antioxidant response and melanin
pigmentation protect these cells from UV radiation and ROS. (c) Lung epithelium relies mainly on a glycolytic metabolism and produces high levels
of lactate even in presence of oxygen. Moreover, lung epithelium is characterized by high lipids synthesis and expression of the metabolism
sensor AMPK. (d) Prostate epithelium is known for accumulation of Zinc and high citrate synthesis as well as acetylated polyamine secretion.clinical results and are therefore considered essential for
the fight against cancer. On the other hand, Treg cells
contribute to the immunosuppressive TME and inhibit
anti-tumor T cell function. Unsurprisingly, in most cases
the presence of Treg cells in the tumor has a negative
effect on patients’ disease outcome. Although T cells are
undoubtedly important players in the body’s immune
response against all cancer types, this response has been
shown to vary between different cancers. Considering the
great metabolic heterogeneity between cancer types, and
even between cancers with the same origin, it is reason-
able to consider that differences in T cell response are a
direct consequence of these metabolic characteristics.
Furthermore, generally, effector T cells share many of
the same metabolic features as most cancer cells (such as
increased aerobic glycolysis and anabolic metabolism).
This leads to metabolic competition between these cells
which ultimately impacts disease progression. For exam-
ple, cancer cells deplete glucose in the TME at the
expense of T cells therefore inhibiting their anti-cancer
functions [7].
In this review we discuss the link between cancer cell
metabolism and T cell response using examples from the
most recent research done on melanoma, lung, breast and
prostate cancers which are some of the most commonwww.sciencedirect.com primary cancer sites. Recently described possible meta-
bolic targets for the treatment of these cancers are out-
lined in Table 1.
Melanoma
Melanoma is one of the most aggressive cancers due to its
ability to disseminate from a small primary tumor.
According to the American Cancer Society there will
be over 100 000 cases of melanoma diagnosed in the
US in 2020 making it the cancer type with the fifth
highest incidence[8]. Melanoma is a highly genetic het-
erogenous type of tumor. The most common oncogenic
mutation is BRAF (in about 45–50% of melanoma
tumors), followed by NRAS (30%) and NF1 (10–15%),
all genes involved in the mitogen-activated protein kinase
(MAPK) pathway, while the remaining 5–10% of mela-
noma are considered as triple wild-type tumors (TWT)
and are driven by other mutations. In physiological con-
ditions, melanocytes are quiescent cells with a low pro-
liferative rate. Their main role is to produce and transfer
melanin to the keratinocytes in order to protect the skin
against UV radiations. In healthy tissue, melanocytes rely
heavily on oxidative phosphorylation and are able to
survive reactive oxygen species (ROS) and UV-induce
damage thanks to melanin and a good antioxidant
response (Figure 1).Current Opinion in Biotechnology 2021, 68:124–143
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Box 1 Main conclusions and future impact of tissue and tumor
specificity of (immune)metabolism in the treatment of different
types of cancer:
Immunotherapy represents a significant breakthrough in modern
medicine. It has improved patients’ lives in many different disease
areas, from autoimmune disorders such as asthma and atopic der-
matitis where it contributes to better quality of life, to cancer where in
some cancer types it can contribute to cancer cure and extended
lifespan. Despite its great success in a subset of cancer types,
immunotherapy is still largely ineffective in many solid tumor types
and in large patients’ subsets. In the quest for a reason why immu-
notherapy is effective in some cancer types (belonging to a specific
histotype or carrying a defined genetic background or mutations),
but not in others, scientists have turned to cellular metabolism for
answers. General characteristics of cancer cell metabolism are well
described, however depending on the organ of origin and some
recurrent mutations in oncogenes or oncosuppressors, cancer cell
metabolism can vary significantly. This is greatly influenced by gen-
eral organ metabolism and/or activation of metabolic pathways/
dependency that are downstream the genetic alterations. Conse-
quently, cancer cell metabolism influences the infiltration and the
activity of immune cells at the primary tumor site. Research is still
lacking on the connection between cancer cell and immune cells
metabolism. Considering T cells are the main targets of immu-
notherapy, they are the obvious choice of cell types to focus on.
What is also obvious is that one solution will not work for all cancer
types, therefore we must study metabolic characteristics and identify
targets, in both T cells or cancer cells, that could be exploited in
order to boost immune infiltration and response within different types
of solid tumors. This kind of approach would likely be useful in
combination with conventional immunotherapeutics such as immune
checkpoint inhibitors or adoptive cell transfer.
The recent research on immune- and cancer cell metabolism in
different cancer types, with different organ of origin, presented here
points to different metabolic pathways as promising new directions
for cancer therapy. For example, in melanoma, recent findings
demonstrate that Inosine supplementation in vivo can increase the
efficacy of anti-PD-1 and ACT treatments [34] as well as points to
methionine as a nutrient specific for CD8+ T cells functionality [35].
In lung cancer, new report presents evidence of the role of deace-
tylase Sirtuin-2 (Sirt2) as a metabolic immune checkpoint, which
negatively regulates key enzyme of glycolysis and oxidative phos-
phorylation in CTLs [54]. In breast cancer, it was shown that
targeting the leptin-STAT3-FAO pathway results in enhanced anti
tumoral CD8+ T cell response in addition to inhibiting cancer cells
[77]. In prostate cancer, a recent report suggests the potential of a
therapeutic effect of IDO inhibition in combination with different
types of therapies, such as with other metabolic targets in addition to
immunotherapy [96].
Currently much of the research is done in a small subset of cancer
models, partly due to the ease of manipulation in some animal
models and the availability of well described cancer cell lines.
However, it is clear that the research done on one cancer type is not
necessarily applicable to other cancer types, or even subtypes within
the same broader cancer type category. Though more time con-
suming, spontaneously occurring tumors (enforced by exposure to
carcinogenic agents or diet) might resemble some of the aspects
that are seen in humans, to a better extent than grafted cancer cells
(even when orthotopic) or oncogene-driven genetically engineered
mouse models (GEMMs). Therefore, more research focusing on
tumors with different organs of origins that resemble more closely
what’s happening in ‘cancer evolution’ is urgently necessary in order
to determine the most effective therapeutic for patients inflicted by
this deadly and heterogeneous disease.
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Triggering of the MAPK pathway in melanoma cancer
cells leads to an upregulation of gene expression related
to glycolysis even in rather normoxic conditions, resulting
in an aggressive phenotype. In BRAF-mutated melano-
mas, the MAPK-activated p90 ribosomal S6 kinase (RSK)
directly phosphorylates PFKFB2, an enzyme involved in
the glycolysis pathway. Phosphorylation-deficient mutant
of PFKFB2 decreased aerobic glycolysis and reduced
tumor growth in mouse models of melanoma [9]. Hence,
it is not surprising that the most common therapies for the
treatment of melanoma patients, namely the inhibitors of
BRAF or MEK (a downstream regulator of MAPK), have
an even greater beneficial effect when combined and this
effect can be partly due to a block in cell metabolism (and
glycolysis). This and other melanoma specific metabolic
characteristics are depicted in Figure 2.
However, there is still a large fractionofpatients that relapse
or become therapy resistant. Recent papers have linked the
resistant phenotype of melanoma tumors with a subset of
cancer cells characterized by an enhanced oxidative metab-
olism. Melanoma cells resistant to MAPK inhibitors
develop an oxidative phenotype, relying more on glutamine
consumption and oxidation [10]. Moreover, the upregula-
tion of ATP-Citrate Lyase (ACLY) specifically activates,
through epigenetic regulation, the MITF–PGC1a axis to
promote mitochondrial biogenesis and melanoma growth.
Interestingly, the combination of MAPK and ACLY inhi-
bition was able to reduce tumor growth [11].
In addition, Gabra et al. showed that dietary glutamine
supplementation reduces tumor growth and improves the
response to BRAF inhibitors. Specifically, it leads to
increased intra-tumoral a-ketoglutarate concentration
that drives hypomethylation of H3K4me3, thereby sup-
pressing epigenetically activated oncogenic pathways in
melanoma [12]
The most relevant cause of morbidity and mortality in
melanoma is metastatic disease. Therefore, a major
research focus is on targeting the metastatic spread of
melanoma cells. The accumulation of lactate in the tumor
microenvironment (TME), consequent to the increased
glycolytic flux has an important role in metastasis forma-
tion. Analysis of patient-derived xenografts and syngeneic
models revealed that cells with the greatest metastatic
potential were able to utilize lactate as a carbon source,
through the upregulation of monocarboxylate transporter
1 (MCT1). Consistently, the inhibition of this transporter
had little effect on tumor growth but induced a strong
impairment on metastasis formation [13]. Other findings
linked AMP-activated Protein Kinase (AMPK) activation
in metastatic lesions with an increased oxidative phos-
phorylation (OXPHOS) and glutamine consumption.
Consequently, these cells showed a higher resistance towww.sciencedirect.com
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SphK1 Inhibition of the SphK1/
PPARg axis in T cells
improves T cell mediated
tumor response
PF543 None In combination
with a-PD-1
[32]
UCP2 Overexpression of UCP2
in cancer cells increase
CD8+ T cell and dendritic
cell anti-tumor immunity
rosiglitazone None In combination
with a-PD-1
[23]
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AKR1B10 promotes metastasis by
limiting the oxidative
stress and enabling fatty
acid oxidation in the
metastatic environment




STAT3 Deletion of STAT3 leads to
increased CD8+ T cell
effector function
None None Unknown [77]
Not
specified
Atg5 Deletion of Atg5 results in
increased glycolysis in
CD8+ T cells and a shift to
a memory phenotype
resulting in decreased
tumor burden in e0771
mouse BC model.





Prostate IDO Increased IDO inhibits
effector T cell functions.
IDO expression could be a
mechanism of immune











Hypoxia Hypoxic regions of tumors
are characterized with























SIRT7 SIRT7 activation inhibits
glycolysis and leads to the
upregulation of FAO.
Deletion of SIRT7 leads to
increased CD8+ T cell
effector functions.





None None Unknown [90]oxidative stress and, therefore, a better survival [14].
Moreover, a transcriptomic analysis of brain metastasis
compared with patient-paired extracranial metastasis
revealed an increase in OXPHOS in brain lesions. Con-
sistently, inhibition of OXPHOS in murine models
reduces the number of metastasis in the brain but not
in the lungs [15].
Upon metastatic disease initiation, melanoma cancer cells
initiate their cross-talk with the adipocytes present in the
subcutaneous region [16]. Adipocytes transfer lipids via
FATP1/SLC7A1 transporter overexpressed in melanoma
cells, boosting cancer cell proliferation and invasion [16].
Fatty acids are also important in the case of Mift-mutated
melanomas, which are part of the TWT group, where the
reduction of this transcription factor decreases the level of
fatty acid saturation, impacting on cancer cell prolifera-
tion [17].Current Opinion in Biotechnology 2021, 68:124–143 In addition to fatty acids and glucose, glutamate also plays
an important role in melanoma. Hyperactivation of glu-
tamate metabotropic receptor (GRM1) in malignant mel-
anoma is an oncogenic driver and GRM1- activated
melanomas were found to exhibit significantly increased
expression levels of glutaminase (GLS). In an in vivo
model of human melanoma cells engrafted in immuno-
deficient mice, concurrent inhibition of glutaminolysis
and glutamate release was shown to suppress tumor
progression [18].
To conclude, although glycolysis and its products
have a strong impact on melanoma tumor aggres-
siveness and progression, recent findings highlighted
the importance of other metabolic pathways, like fatty
acid oxidations or glutaminolysis, that can consider-
ably affect cancer cells proliferation and therefore
tumor progression.www.sciencedirect.com
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Tissue specific cancer metabolism. (a) Breast cancer specific metabolism. ER + BC subtype is characterized by Reverse Warburg metabolism –
influencing neighboring stromal cells to upregulate OXPHOS and channel metabolites to support cancer cells. Regarding fatty acids, ER + BC
prefers FAS and FAO while TNBC relies more on uptake and storage of exogenous fatty acids. HER + BC relies heavily on FAS and has high rates
of fatty acid storage. Additionally, TNBC exhibits classical Warburg metabolism and is also dependent on cholesterol synthesis. ER + BC has
upregulated triacylglycerols (TG), while TNBC and HER + BC is known to downregulate TG. (b) Melanoma metabolism. Melanoma primary tumors
have increased glycolysis (mainly driven by MAPK), increased glutaminolysis (due to hyperactivation of GRM1) and augmented oxidative
phosphorylation epigenetically potentiates by ACLY. Moreover, dietary glutamine supplementation has been showed to reduce tumor growth.
Melanoma metastases have been shown to have increased lactate uptake due to the upregulation of MCT1, augmented OXPHOS and increased
fatty acid metabolism. (c) Lung cancer metabolism. SCLC is characterized by an increased MEK5/ERK5 kinases activity which promotes
proliferation and controls lipid metabolism. NSCLC has been shown to accumulate glycogen in the nucleus and express higher GLDC,
mechanisms that rewire cancer metabolism and sustain its growth. Different subtypes harbor also metabolic differences and in particular, in
adenocarcinoma (AdC) higher expression of MGST1 has been detected and associated with poor prognosis, whereas squamous cell carcinomas
(SCC) are characterized by higher glycolysis and mTOR activity, inhibition of which leads to a preferential glutamine metabolism. Oncogenic
mutations are often found in NSCLC, inducing different metabolic pathways. KRAS activating mutations induce glutamine consumption and
increased amino acids uptake and synthesis. When KRAS mutations are accompanied by KEAP1 loss of function, cancer cells show a higher PPP
and AA uptake, whereas, in presence of LKB1 loss of function, they show an increased autophagy to sustain an elevated macromolecular
biosynthesis. Additionally, in KRAS mutant, LKB1 deficient NSCLC, activating mutation of KEAP1, induce higher glutamine consumption.
Moreover, activating mutations in EGFR promote a glycolytic addictive metabolism, whereas loss of function mutations in SMARCA4 promote
dependency on OXPHOS. (d) Prostate cancer metabolism. Malignant prostate cells convert to citrate oxidation and a decrease in Zinc
concentrations, together with increased demand for intracellular polyamines. Androgen receptor signaling in prostate cells upregulates expression
of DRP1 which leads to increased OXPHOS and lipogenesis.T cell metabolism in melanoma
Together with BRAF and MEK inhibitors, immunother-
apy has become an important treatment option for mela-
noma patients. The discoveries of immunotherapy and in
particular ICI, had a strong impact on the survival of
melanoma patients. However, there is still a large number
of patients that do not benefit from this treatment. In
melanoma, T cells constitute a high percentage of the
immune infiltrate, but they often retain a pro-tumoral or
exhausted phenotype. Recent advances have shown how
targeting melanoma cell metabolism can change the
TME, improving the fitness of the endogenous T cells
and, therefore, the efficacy of immunotherapies
(Figure 3). Cascone et al., for example, have linked the
augmented glycolysis of a fraction of cancer cells with the
resistance to ACT in melanoma patients [19].www.sciencedirect.com Glycolysis-related protein, in fact, are among the most
studied targets in combinational therapies with the ulti-
mate goal to improve the outcome of immunotherapy
treatments. Consistently, restricting glycolysis using
diclofenac, as a non-specific inhibitor of both lactate
transporters MCT1 and MCT4, reduces cancer cell pro-
liferation preventing them from using lactate as a carbon
source. This inhibitor affects also T cell metabolism by
decreasing their proliferation, but not their activation or
cytokine production. Consequently, diclofenac treatment
increases the response to a-PD-1, improving mice sur-
vival [20]. Moreover, Najjar et al. compared an array of
melanoma cell lines characterized by glycolytic or oxida-
tive metabolism. They demonstrate that a low oxidative
metabolism results in a less hypoxic microenvironment
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Metabolic factors influencing T cell responses in different tumor types. (a) T cell metabolism in response to breast cancer. Leptin expressed by
mammary adipocytes activates STAT3 in CD8+ T cells, which induces FAO and inhibits glycolysis leading to decreased effector function. Deletion
of Atg5 in T cells results in a shift to a memory phenotype and an increase of proinflammatory cytokine expression. Inhibition of FABP5 leads to
increased Treg suppressive function. (b) T cell metabolism in melanoma. Compromised activity of Enolase I leads to impaired glycolysis and
oxidative metabolism and reduced effector cell function. Exhausted T cells present mitochondrial dysfunction. FAO and methionine are necessary
to maintain TIL functionality. LDHA inhibition together with IL-21 treatment of T cells before ACT results in increased Tscm polarization and a more
effective anti-tumoral response. CD36 enhances lipid uptake in Treg cells. Targeting the S1P-PPARg pathway or GSH production mediated by
GCLC decreases Treg polarization and function. (c) T cell metabolism in Lung cancer. Sirt-2 acts as a metabolic immune checkpoint. Its inhibition
enhances T cells metabolic fitness and effector function. Short term starvation (STS) increases CD8/Treg ratio and synergizes with anti-PD-L1
treatment. (d) T cell metabolism in prostate cancer. IDO expression leads to a decrease in tryptophan and subsequently in the inhibition of
effector T cell function.ultimately reducing tumor growth and improving a-PD-1
response [21]. In contrast with these findings, a proteo-
mic analysis of different cohorts of melanoma patients
treated with a-PD-1 or ACT, highlighted an increased
lipid and oxidative metabolism in patients that responded
better to the treatment. Additionally, augmented mito-
chondrial metabolism was linked with a higher antigen
presentation and IFNg signaling [22]. Accordingly, dele-
tion of Acetyl-CoA acetyltransferase to impede oxidative
metabolism, strongly reduced MHC class 1 expression
and increased tumor growth [22].
Independently from glycolysis, another study shows how
Uncoupling protein 2 (UCP2) expression in melanoma
patients correlates with T cell infiltration and prolonged
survival rate. Its overexpression in cancer cells was found
to change the cytokines composition of the TME,
increasing CD8+ T cell infiltration in a dendritic cells-
dependent manner and finally sensitizing tumors to PD-1
treatment [23]. This effect seems to be independent fromCurrent Opinion in Biotechnology 2021, 68:124–143 the uncoupling function of UCP2, but the underlying
mechanism is still unclear.
Gut microbiota composition can also influence the
response to ICI. Analysis of serum and stool microbiota
of two different cohorts of melanoma patients revealed an
association between the two short chain fatty acids
(SCNA) butyrate and propionate with clinical outcomes.
A high concentration of these SCNA correlates with
resistance to a-CTLA4. In mice, treatment with butyrate
reduces the efficacy of a-CTLA-4 treatment leading to a
decrease in CD80 and CD86 expression on the surface of
dendritic cells and a decrease in memory T cells number
[24].
On the other hand, targeting the metabolism of T cells
can also have a strong impact on their function and
polarization. TILs in human melanoma display an
impairment of both glycolytic and oxidative metabo-
lism, due to the compromised activity of enolase I, anwww.sciencedirect.com
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its function improves both glycolytic and oxidative
metabolism, boosting effector T cell functions [25].
Interestingly, a transcriptomic analysis aimed to ana-
lyze the different effects of IL-2 and IL-21 on T cell
metabolism, highlighted LDHA as one of the most
differently expressed genes. IL-2 treatment increases
T cell glycolytic flux and polarizes them towards an
effector phenotype, whereas IL-21 maintains a more
quiescent metabolism and promotes stem cell memory
T cells (Tscm). Accordingly, LDHA inhibition com-
bined with IL-21 treatment of T cells before ACT,
increases the formation of Tscm cells, resulting in a
more profound anti-tumor responses and a prolonged
host survival [26]. In addition, CD8+ T cells isolated
from murine and human melanoma tumors demonstrate
an increased fatty acid uptake and oxidation [27]. In
particular, catabolism of fatty acids is necessary to
maintain TIL functionality [27]. Another study
showed how exhausted T cells have defect in oxidative
phosphorylation. An antioxidant treatment was enough
to restore T cells functions [28].
Treg cells infiltrating different types of tumors, including
melanoma, have an enhanced lipid uptake mediated by the
transporter CD36, which also fuels oxidative mitochondrial
fitness via PPAR-b. Accordingly, genetic deletion or phar-
macological targeting of CD36 decrease Treg number in
the tumor, create a less suppressive TME and synergize
with a-PD-1, thus leadingto a reduced tumorgrowth[29].
Interestingly, not only fatty acid uptake is important for
Treg cells proliferation, but also FAS. Both glycolytic and
oxidative pathways are necessary to fuel FAS and allow
Treg expansion in the TME. The ability of this cell type to
utilize different metabolic routes confers them a growth
advantage as compared to conventional T cells [30].
Moreover, Treg cells display a highly antioxidant pheno-
type mediated by reduced glutathione (GSH). Specific
deletion of Gclc, a subunit of the glutamate cysteine ligase
involved in GSH synthesis, revealed how targeting GSH
production in Treg cells reduces serine metabolism and
impacts on the functionality of this T cell subset. In vivo
Gclc deletion induces a strong autoimmune effect and
improves anti-tumor immunity. In particular, ACT of
Gclc depleted Treg cells together with T effector (Teff)
cells had a greater anti-tumoral activity compared to ACT
with wild-type Treg and Teff cells, due to their reduced
immunosuppressive effect [31].
Furthermore, it is known that Sphingosine 1-phosphate
(S1P) controls T cell egression from lymphoid organs and
Treg and Th17 cell polarization. Chakraborty et al. dem-
onstrated that T cells lacking sphingosine kinase 1
(SphK1), the enzyme involved in the production of
S1P, maintain T central memory phenotype and decrease
their polarization towards Treg cells. They proved thatwww.sciencedirect.com these cells exhibit an increased OXPHOS and lipolysis
mediated by PPARg and that targeting the S1P- PPARg
axis improves the anti-tumor response [32].
Finally, inhibition of glutamine metabolism by the use of
a pro-drug of 6-diazo-5-oxo-L-norleucine (DON), a glu-
tamine antagonist that becomes active in the TME upon
enzymatic cleavage, has a strong impact on the overall
metabolism of melanoma cells and affects their prolifera-
tion. Whereas the same molecule has the opposite effect
on T cells by increasing their proliferation and reducing
exhaustion and anergy. T cells, differently from cancer
cells, are able to utilize acetate as carbon source to fuel the
TCA, thanks to the up-regulation of acyl–coenzyme A
synthetase short-chain family member 1 (ACSS1). There-
fore, the use of this inhibitor in mouse models shows a
strong decrease in tumor growth and a synergistic effect
with a-PD1 treatment [33].
Moreover, Teff cells are able to utilize inosine as an
alternative energy source when glucose is missing, fueling
their proliferation and effector functions. On the contrary
different cancer cell lines seem to be unable to use the
same metabolite. Consistently, inosine supplementation
in vivo increases the efficacy a-PD-1 and ACT treatments
[34].
An alternative study highlights instead the importance of
methionine as a nutrient specific for CD8 T cells func-
tionality. The deprivation of methionine in the TME
caused by its highly consumption from cancer cells
decreases dimethylation at lysine 79 of histone H3
(H3K79me2) in T cells, leading to a low expression of
STAT5 and impaired T cell immunity. Consistently,
pharmacological or genetical inhibition of SLC43A2 in
the tumor improves response to immune-checkpoint
therapy [35].
In conclusion, recent work brought to attention the het-
erogeneity of melanoma metabolism highlighting the
effect of cancer cell metabolism on T cell functionality
and vice versa. In addition, these last findings underline
the importance of studying metabolic vulnerabilities spe-
cific to cancer cells, in order to open new possibilities for
the creation of specific therapies targeting cancer cells
while at the same time promoting anti-tumor immune cell
functions. While contradictory results leave space for
further study regarding the contribution of oxidative
metabolism to immunotherapy resistance, growing evi-
dences indicate the importance of targeting glycolysis and
to further study the role of fatty acids in the polarization
and functionality of T cells, in particular of Treg cells,
opening the way for new possible treatments.
Lung
LC displays the highest incidence worldwide (2 million in
2018) as well as being the leading cause of cancer relatedCurrent Opinion in Biotechnology 2021, 68:124–143
134 Systems biologydeaths worldwide (1.7 million in 2018), due to a combi-
nation of late diagnosis and poor treatment options. This
tumor type is highly heterogeneous and categorized into
two main groups: Non-Small Cell Lung Cancer
(NSCLC), which represents 80–85% of LC patients,
and Small Cell Lung Cancer (SCLC), that affects the
neuroendocrine tissue of the lungs and occurs in 15–20%
of the cases. Based on the histology NSCLC is further
subcategorized into Adenocarcinoma (AdC), Squamous
cell carcinoma (SCC) and Large cell carcinoma (LCC).
Smoking is the first risk factor for LC, and is the cause of
80–90% of the cases. This holds true particularly for
SCLC, that develops almost exclusively in heavy smok-
ers, and for the SCC subtype among the NSCLC. In
healthy conditions, lung epithelium forms a conduit for
gas exchange, but it is also engaged in more specialized
energy-consuming activities such as airway clearance,
through phagocytosis and ciliary motility, and production
of pulmonary surfactant, supported by a high cellular lipid
synthesis. For these reasons, lung epithelium is one of the
tissues with the highest glucose consumption accompa-
nied by an elevated lactate production, to minimize local
oxygen utilization, thus enhancing its delivery to the
other tissues. Moreover, energy production and usage
are fine-tuned by the metabolic regulator AMPK, highly
expressed in this tissue (Figure 1) [36]. LC specific
metabolic features are represented in Figure 2.
In 2015 three different drugs, namely nivolumab, pem-
brolizumab (targeting PD-1), and atezolizumab (targeting
PD-L1), received FDA approval for the treatment of
advanced stage NSCLC, leading to an improve in survival
and in some cases to tumor regression. However, 80% of
NSCLC patients do not respond to immunotherapy with
some even undergoing hyper progression. Therefore, it is
becoming important to identify biomarkers predictive of
response or resistance to immune checkpoint therapy,
and ways to improve such response or sensitize the tumor
to ICI.
Lung cancer metabolism
NSCLC, as many other tumor types, relies on a high
glucose and pyruvate consumption to sustain its growth.
Among all the glycolytic pathways, glycine decarboxylase
(GLDC), which catabolizes glycine to yield 5,10-methy-
lenetetrahydrofolate (MeTHF), is frequently upregu-
lated in various types of cancer including lung, prostate
and brain. Particularly in LC, it supports tumor growth, as
shown by the fact that GLDC inhibition impairs pyruvate
metabolism, thus inducing tumor regression both in vitro
and in vivo [37]. Increased proliferation and mitochondrial
activity can be responsible for a higher production of
ROS, deleterious products for cell homeostasis. In this
context, and differently from what aforementioned in the
context of melanomas, Glutathione S-transferases (GSTs)
are important for cells detoxification. In particular, the
microsomal isoform 1 (MGST1) is significantly increasedCurrent Opinion in Biotechnology 2021, 68:124–143 in human AdC, compared to normal lung tissue, and its
expression is associated with poor prognosis. Accordingly,
MGST1 knockdown, by acting on the mitochondrial
apoptotic related proteins, induces apoptosis in AdC cells
and suppresses in vivo tumor growth [38].
NSCLC is also characterized by a multiplicity of recur-
rent oncogenic driver mutations, underlining a high vari-
ability even among the same histological NSCLC sub-
type. Different genetic alterations can induce diverse
metabolic adaptation and immune response, that can
be exploited for therapeutic application. A great example
in this sense is provided by the Epidermal Grow Factor
Receptor (EGFR), a tyrosine kinase receptor, altered in
15–20% of AdC. EGFR-induced glycolysis sustains can-
cer proliferation and maintains, at the same time, EGFR
stability, thus creating a positive loop [39]. Therefore, the
use of Tyrosine Kinase Inhibitors has been effective for
the treatment of patients harboring EGFR mutations.
KRAS, a member of the Ras family small GTPases, is
involved in the transmission of extracellular mitogenic
signals, and its aberrant activation sustains cellular pro-
liferation and survival through RAF-MEK and PI3K/
AKT pathways. Therefore, KRAS mutations drive multi-
ple cancers, including LC, where they are found in more
than 30% of NSCLC, and mostly in AdC. Despite its high
incidence, differently from EGFR, KRAS is difficult to
target. Indeed, the first KRAS effective inhibitor is the
small molecule AMG510, which was recently proved to
induce tumor regression alone and in combination with
ICI in a model of colorectal cancer and is now in clinical
trial for multiple KRAS-mutant tumors, including
NSCLC, for which, based on the preliminary data, it
resulted in partial response or stable disease [40]. In
an attempt to find alternative therapeutic strategies to its
direct inhibition, the role of mutant KRAS in NSCLC
metabolism is being deeply studied. The work of Gwinn
D.M. et al., identified KRAS as a key regulator of nutrient
deprivation response. Through PIK3-NRF2, KRAS acti-
vates ATF4 inducing the expression of its downstream
targets, such as glutamine transporter SNAT1 and aspar-
agine synthetase (ASNS), thus regulating amino acid
uptake and asparagine biosynthesis [41]. KEAP1, a key
player in ROS detoxification, is a negative regulator of
NRF2. Interestingly KRAS-driven LC are frequently
paired with KEAP1 loss of function mutations. In this
context, KEAP1 loss rewires KRAS-mutant tumor metab-
olism, on one hand by reinforcing ATF4-mediated amino
acid uptake and on the other by inducing the pentose
phosphate pathway (PPP), inhibition of which abrogates
tumor growth [42]. KRAS activation is also commonly
coupled with loss of LKB1 function. Patients character-
ized by KRAS-mutant LKB1-deficient (KL) develop
more aggressive tumors, show high frequency of metas-
tasis and are resistant to immunotherapy. Loss of LKB1
sustains KRAS-driven uncontrolled proliferation, even inwww.sciencedirect.com
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molecular biosynthesis and inducing autophagy to fuel
the reprogrammed metabolism. Consistently, deletion of
the autophagy essential gene Atg7 abrogates initiation
and growth of KL tumor, suggesting a new therapeutic
strategy for this subset of NSCLC [43]. Furthermore, in
KRAS-driven AdC, LKB1 loss induces often KEAP1
activation (KLK tumors). By acting cooperatively, this
set of mutations maintains energetic and redox homeo-
stasis in a glutamine dependent manner, thus enhancing
KLK tumors sensitivity to glutaminase inhibition [44].
LKB1 is also the main positive regulator of AMPK.
Interestingly, in a KRAS-mutant mouse model, genetic
deletion of AMPK does not phenocopy LKB1 loss and
promotes instead tumor regression, pointing out that, in
nutrient restrictive conditions, a minimal level of AMPK
activity is required for NSCLC growth [45].
SCC are highly aggressive, highly glycolytic and, com-
pared to AdC, show differential expression of a set of
genes involved in glucose and glutamine catabolism as
well as nucleotide and glutathione biosynthesis [46].
Moreover, SCC, unlike AdC, have frequent mutations
in the PIK3/AKT pathway, that result in an overactivation
of mTOR and tumor progression. However, single thera-
pies inhibiting this pathway have limited clinical efficacy.
As shown by an in vivo metabolic and molecular profiling,
SCC can adapt to chronic mTOR inhibition and glycoly-
sis suppression via the GSK3a/b pathway, which upre-
gulates glutaminolysis through the induction of GLS,
providing a proof of concept for combinatorial GLS
and mTOR inhibition [47].
Epigenetics plays also an important role in metabolic
rewiring and tumor progression. In NSCLC the activation
of Proline Dehydrogenase (PRODH) mediated by the
chromatin remodeling factor LSH, induces tumor growth,
epithelial to mesenchymal transition (EMT) and the
expression of inflammatory cytokines including CXCL1
and IL17C[48]. Another example is the SWI/SNF chro-
matin remodeling complex, which is also found altered,
mostly in adenocarcinoma. In particular, the chromatin
rearrangement mediated by the inactivation of
SMARCA4, part of the complex, leads to enhanced oxy-
gen consumption and respiratory capacity. As a result,
SMARCA4 mutant xenografts show a dependence on
OXPHOS and a marked sensitivity to its inhibition
[49]. Moreover, unlike physiological lung tissue, in
NSCLC decreased abundance of malin, an E3 ubiquitin
ligase, prevents nuclear translocation of glycogen phos-
phorylase and induces nuclear accumulation of glycogen,
thus impairing histone acetylation and sustaining tumor
growth [50].
Because of the high heterogeneity of LC, it may be
important to unveil the relationship between molecular
and metabolic cell features on a larger scale. In this sense,www.sciencedirect.com an in vitro extensive characterization of metabolic fluxes
in a high variety of NSCLC cell lines, proved to be useful
in predicting dependency on specific metabolic pathways
and sensitivity to metabolic drugs such as pemetrexed, an
antimetabolite currently in use for NSCLC therapy [51].
SCLC is frequently characterized by loss of function
mutation in tumor suppressor genes TP53 and RB1,
but, unlike NSCLC, it rarely presents oncogenic driving
mutations, thus limiting therapeutic options. In this
regard, through a genetic screening approach, Li et al.
uncovered SCLC sensitivity toward disruption of the
pyrimidine biosynthesis pathway and identified dihy-
droorotate dehydrogenase (DHODH) as a new promising
therapeutic target [52]. Another pathway that has been
studied in SCLC is the MEK5–ERK5 axis. This dual
kinase axis is known to be responsible for increased
growth and metastasis and lower overall survival in dif-
ferent tumor types including breast, prostate and colon
cancer. This is also true for SCLC, where MEK5 and
ERK5 play a critical role in cell survival by controlling
lipid metabolism. Notably, the loss of MEK5/ERK5
perturbs cholesterol synthesis, making SCLC sensitive
to mevalonate inhibitions trough statins [53].
T cell metabolism in lung cancer
An important parameter for the response to ICI seems to
be the evaluation of PD-1/PD-L1 expression on both
cancer and immune cells, particularly TILs and CD8+
cytotoxic T cells (CTLs). In this context it has been
shown that in human NSCLC the presence of CD8+
TILs expressing high levels of PD-1 is predictive of
response and survival upon a-PD-1 treatment. Despite
the numerous studies analyzing the infiltration of T cells
in LC, little is known about their metabolic features in
the context of specific nutrients deprived microenviron-
ment. A highly relevant recent discovery points to the role
of deacetylase Sirtuin-2 (Sirt2) as a metabolic immune
checkpoint, which negatively regulates key enzyme of
glycolysis and oxidative phosphorylation in CTLs [54].
Moreover, the fact that Sirt2 KO can enhance T cells
fitness and effector function, leading to an effective
antitumor immune response, strongly supports T cells
metabolic manipulation as a promising strategy to
improve the efficacy of the current immunotherapy regi-
mens [54].
As a possible way to improve immunotherapy in NSCLC,
Ajona et al. showed that short term starvation sensitizes
tumors to a-PD-1 treatment by reducing circulating
insulin-like growth factor 1 (IGF-1) and downregulating
IGF-1 receptor (IGF-1R) signaling in tumor cells (Fig-
ure 3). Moreover, a combination of IGF-1R inhibition and
PD-1 blockade impaired LC progression by boosting
intra-tumoral CD8+/Treg ratio, supporting the clinical
evaluation of IGF-1 modulators together with a-PD-1
treatment [55].Current Opinion in Biotechnology 2021, 68:124–143
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providing a strong rationale for the use of ICI. Indeed,
despite the limited added survival benefit, FDA recently
approved the use of atezolizumab (a-PD-L1) together
with chemotherapy as first line treatment in extensive
stage SCLC (i.e. SCLC spreading far from the primary
site, in the lungs themselves or elsewhere). However, like
NSCLC, a large number of patients do not respond to the
treatment. In this scenario, studies have been conducted
to increase T cells infiltration by acting on cancer cells,
but manipulation of T cells metabolism has not been
exploited so far.
To conclude, an extensive effort has been done to
describe the heterogenic lung cancer metabolism. How-
ever, T cell metabolic features associated to these differ-
ent microenvironments are still poorly understood, under-
ling the need for further investigation. In this direction,
single cell RNA sequencing aiming to perform large scale
NSCLC phenotyping of stromal cells in general or T cells
could be useful to improve the outcome of current
immunotherapies and to define new treatment options
[56,57].
Breast
Breast cancer (BC) is the most commonly diagnosed
cancer in women and has the second highest incidence
overall worldwide [58]. Cancers arising in the breast tissue
are diverse in their (epi)genetic and morphological fea-
tures as well as metabolic profiles. BC can be classified
into three distinct molecular groups based on expression
of hormonal receptors (estrogen and/or progesterone
receptor positive), human epidermal growth factor recep-
tor HER2 positive, and triple negative tumors (TNBC) -
lacking estrogen receptor, progesterone receptor and
HER2 [59]. This classification is the major characteristic
that determines the therapeutic approach to treat the
disease. However, it has been shown that even within
each of those groups there can be considerable molecular
heterogeneity.
The correlation between the abundance of CTLs and
favorable disease outcome has recently been demon-
strated in a cohort of 187 BC patients [60]. Furthermore,
higher CD8+ T cells infiltration can be used as a predic-
tive factor of response to non-adjuvant chemotherapy for
patients with HER+ and TNBC. In regard to Treg cell
infiltration, there is a considerable disparity among the
different BC subtypes. Most studies find that high Treg
cell infiltration correlates with poor disease outcome [61].
However, there are some studies which have found the
opposite to be true in TNBC [62].
Breast cancer cell metabolism
Different types of BC also differ in their metabolic
profiles (Figure 2). TNBC subtype primarily utilizes
the Warburg effect metabolism characterized by highCurrent Opinion in Biotechnology 2021, 68:124–143 glucose uptake and lactate secretion even in the presence
of oxygen [63]. Additionally, TNBC relies heavily on
uptake and storage of exogenous fatty acids while ER+
BC subtype prefers fatty acid synthesis (FAS) and oxida-
tion. Furthermore, ER+ BC subtype displays the reverse
Warburg metabolic effect – where neighboring stromal
cells are induced to undergo aerobic glycolysis and then
transfer the catabolites to the cancer cells for them to use
in OXPHOS to support their proliferation. HER2+ cancer
subtype can be characterized by a unique Warburg like
metabolic effect which is heavily reliant on FAS and has
been shown to have increased levels of stored fatty acids
[64]. Considering that lipid metabolism differs substan-
tially between different subtypes Eiriksson et al. sought to
determine if the differences in the lipidome could be
used as a marker to distinguish the different subtypes for
diagnostic purposes [65]. Analysis of the lipidome of
different BC subtype cell lines showed that cells of the
luminal BC subtype (ER and PgR positive) have
increased abundance of triacylglycerols (TG) with mod-
erate or multiple unsaturated fatty acid chains, while
these lipids are significantly downregulated in HER2
and TNBC subtypes [65]. Furthermore, concerning lipid
metabolism, cholesterol biosynthesis was shown to be
essential for breast cancer stem cell propagation [66].
Additionally, inhibition of cholesterol synthesis enzymes
leads to significant reduction in TNBC mammosphere
growth and propagation [66], thus providing evidence for
the potential of targeting cholesterol synthesis pathway in
the treatment of TNBC patients. Lipid metabolism
reprograming has also been extensively linked to the
development of resistance to kinase inhibitors in BC [67].
A recent study has shown that EMT in BC is associated
with the attenuation of succinate dehydrogenase (SDH)
[68]. This enzyme is part of the mitochondrial electron
transport chain and therefore an important player in
energy metabolism. With this study Røsland et al. pro-
vide further proof of the importance of mitochondrial
processes in EMT and highlight its potential as a thera-
peutic target. Additionally, inhibition of estrogen-related
receptor a (ERRa) in TNBC cell lines leads to reduced
pyruvate entry into the mitochondria resulting in cells
becoming more dependent on glutamine and glucose
oxidation and ultimately leads to cancer cells being more
sensitive to GLS and PPP inhibitors [69]. This high-
lights the need to evaluate the interplay between the
different metabolic factors and the potential of a cascade
effect between different metabolic pathways when con-
sidering therapeutic approaches targeting cancer
metabolism.
Since the development of metastasis correlates with poor
prognosis, it is important to identify factors that contrib-
ute to a more invasive BC phenotype. Aldo-keto reduc-
tase AKR1B10 has been identified as one such factor.
AKR1B10 promotes metastasis by limiting the oxidativewww.sciencedirect.com
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metastatic environment [70]. This metabolic alteration
has been shown to be important only for metastatic
colonization but not for primary tumor growth, therefore
AKR1B10 inhibition represents a potential treatment
option for advanced BC. Additionally, high expression
of AKR1B10 could be used to identify patients with a
higher risk of metastasis. Even though the connection
between metastasis and AKR1B10 expression has so far
only been shown in BC, AKR1B10 is highly expressed in
other cancer types, including lung [71] and pancreas [72],
suggesting the possibility to explore this factor as a
therapeutic target in multiple cancer types.
Considering the emerging new research, fatty acid metab-
olism stands out as the group of metabolic processes
which have been shown to be most important for BC
cell growth and development of resistance to many exist-
ing therapeutic approaches. Further research is necessary
to determine how targeting different metabolic pathways
can diminish cancer cell proliferation while at the same
time boosting T cell fitness within the TME, ultimately
leading to improved disease prognosis.
T cell metabolism in breast cancer
Out of the different BC subtypes, TNBC is considered as
the one to most likely respond to ICI treatment. This is
largely due to the fact that TNBC generally has a higher
TIL infiltration [73], as well as high expression of PD-L1
[74], which is a direct target for this class of immunother-
apy. In fact, based on the results of a recent clinical trial
(NCT02425891) [75], the FDA granted accelerated
approval for a-PD-L1 treatment using a monoclonal
antibody in combination with chemotherapy for treat-
ment of PD-L1 positive, unresectable, locally advanced
or metastatic TNBC. More on the current state of immu-
notherapy in TNBC has been recently reviewed else-
where [76].
STAT3 activation and CD8+ T cell functions have been
correlated in obesity-associated BC. Deletion of STAT3
in obese mice, who are known to spontaneously develop
tumors, was shown to decrease FAO, increase glycolysis
and improve CD8+ T cell effector functions, leading to
reduced BC incidence in these mice [77]. Additionally,
leptin, which is abundant in mammary adipocytes and
surrounding fat tissue, was shown to inhibit CD8+ T cell
effector functions by activating STAT3, consequently
inducing FAO and reducing glycolysis. Furthermore,
leptin is one of the key adipokines produced by breast
tissue adipocytes (Figure 1) that can promote BC stem
cell self-renewal and chemo-resistance [78]. Therefore,
targeting the leptin-STAT3-FAO pathway may result in
enhanced anti tumoral CD8+ T cell response in addition
to inhibiting cancer cells in obesity associated BC
(Figure 3).www.sciencedirect.com Lipid chaperone fatty acid binding protein 5 (FABP5)
expression is increased in tumor infiltrating Treg cells
isolated from human BC [79] and murine subcutaneous
E.G7 tumor model [80]. Curiously, in vitro studies show
that inhibition of FABP5 leads to mitochondrial altera-
tions and increased suppressive function of Treg [80].
Because there is a limited amount of lipids in the tumor, it
is believed that Treg cells increase FABP5 expression as
an adaptive response to the low-lipid environment. This
and other indications suggest that the metabolic needs of
Treg cells, both in vivo and in vitro, are likely dynamic and
depend on their activation stage as well as the nutrient
microenvironment at the site of activation [80].
A bioinformatics study, which analyzed gene expression
data from 4921 cancer patients, determined that elevated
expression of the hepatic lipase LIPC correlates with
higher infiltration of both myeloid and lymphoid cells
in several cancer types including breast, melanoma and
NSCLC [81]. In contrast high expression of aldehyde
dehydrogenase seven family, member A1 (ALDH7A1)
correlates with lower infiltration of immune effector cells.
The mechanism governing these correlations is still to be
investigated.
Autophagy is a cellular process linked to immune
response in various infections and recently also to anti-
tumoral CD8+ T cell immunity. Mice with a deficiency in
the genes essential for autophagy Atg5, Atg14, or
Atg16L1, have a significant decrease in the growth of
breast, prostate and colorectal tumors [82]. Additionally,
T cells with a deletion in the Atg5 gene exhibit a shift to a
memory phenotype along with an increase of proinflam-
matory cytokines IFNg and TNFa. In vitro and in vivo
mechanistic studies done in syngeneic e0771 model of BC
indicate that the suppression of autophagy caused by
deletion of Atg5 leads to increased glycolysis in CD8+
T cells and a decrease in the concentrations of S-adeno-
sylmethionine (SAM) [82]. This metabolic alteration
consequently leads to changes in histone methylation,
which is associated with increased expression of effector
and metabolic genes, resulting in a memory T cell phe-
notype. Disruption of autophagy in T cells has therefore
been proposed as a therapeutic strategy that could
enhance immunotherapeutic effort in human cancers.
With the breakthrough of CRISPR/Cas9 technology,
genomic screens represent a promising approach for
new target discovery and the advancement of immuno-
therapy. One such screen was done on CD8+ T cells
selecting for tumor infiltration in mouse models of TNBC
in the context of immunotherapy [83]. This screen
identified several genes associated with higher CD8+ T
cell infiltration, activation and effector functions. One of
these genes is Dhx37, encoding for an RNA helicase,
which, when deleted in CD8+ T cells, improved ACT
efficacy in an orthotopic BC mouse model utilizing theCurrent Opinion in Biotechnology 2021, 68:124–143
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focused screening libraries, such as those targeting meta-
bolic genes, could potentially lead to the discovery of
even more promising druggable targets affecting T cell
infiltration and fitness within the TME.
Prostate
Prostate cancer is the second most commonly diagnosed
cancer type in men, behind LC, and represents a major
cause of male morbidity and mortality. In 2018 alone,
there were over 1.2 million new diagnosis reported world-
wide and close to 360 000 deaths related to prostate
cancer[58]. Despite some heterogeneity in prostate can-
cer among the patient population, there is a generalized
phenotype that is common to all patients including some
metabolic alterations observed in prostate cancer cells.
These metabolic events are distinct between the differ-
ent stages of disease - early versus late stage. The Gleason
grading system is commonly used to diagnose and classify
the severity of prostate cancer using histopathological
examination and scoring of the cells biopsied based on
its resemblance to healthy prostate cells. Score 6 is given
to low-grade cancers, score 7 to intermediate, and score 8–
10 indicates high-grade and most aggressive prostate
cancer. Healthy prostate epithelium cells are known for
the high accumulation of Zinc as well as citrate synthesis
and a lack of citrate oxidation (Figure 1).
Depending on the characteristic of the tumor, prostate
cancer patients are subjected to one or more treatments,
including surgery, androgen deprivation therapy and
chemotherapy. However, there are very limited treat-
ment options for metastatic disease and immunotherapy
has not been proven effective in prostate cancer. Prostate
cancer is classified as a ‘cold’ tumor with minimal T cell
infiltration, with several factors contributing to its non-
inflamed phenotype. Prostate cancer is characterized by
relatively few somatic mutations, compared to other
cancer types, and consequently low expression of neoan-
tigens that could trigger a T cell response. Other factors
contributing to this non inflamed phenotype of prostate
cancer are downregulation of MHC Class I expression,
PTEN loss and a deficiency in IFN1 signaling [84]. It is
possible that the use of drugs targeting metabolism could
synergize and render these tumors susceptible to immu-
notherapy such as ICI. Despite this unfavorable TME, it
has recently been shown that it is possible to isolate
functional and anti-tumor reactive TILs from clinical
prostate cancer samples [85], therefore providing a ratio-
nale for further investigation into TIL immunotherapy
for prostate cancer.
Prostate cancer cell metabolism
In cancer cells there is a metabolic shift in this respect and
malignant prostate cells convert to a citrate oxidizing
phenotype accompanied by a decrease in zinc concentra-
tions (Figure 2). In line with this, prostate cancer cellsCurrent Opinion in Biotechnology 2021, 68:124–143 have been shown to utilize the TCA cycle and OXPHOS
more compared to benign prostate cells. Prostate cancer
cell metabolism is unique in that it does not generally
display the Warburg effect in glucose metabolism that
most other cancers adhere to. The Warburg effect and
increased glucose metabolism together with lactate secre-
tion can only be observed in the late stages of disease and
after accumulating multiple mutations [5]. Using in vivo
hyperpolarized MRI imaging followed by tissue histopa-
thology, Granlund et al. demonstrate that tumors with
increased Gleason grades had significantly increased
levels of lactate [86]. Furthermore, increased metabolism
of pyruvate to lactate is augmented in tumors with homo-
zygous deletion of the PTEN gene.
The remodeling of OXPHOS in prostate cancer has
recently been linked to mitochondrial DNA (mtDNA)
mutations and differentially expressed mitochondrial
genes, especially in high-grade cancers [87]. Specifically,
increased mutations in mitochondrial Complex I encod-
ing genes, correlate with a significant increase in succinate
oxidation.
Prostate epithelial cells exhibit a high rate of acetylated
polyamine secretion in the prostate lumen. This behavior
is maintained by prostate cancer cells, who additionally
also require high concentrations of intracellular polya-
mines leading to an increased demand for connected
metabolic pathways [88]. An interesting new therapeutic
approach has been proposed to target this metabolic
vulnerability of prostate cancer [89]. In order to cause
apoptosis, metabolic stress is induced in prostate cancer
cells by using a polyamine analog N1,N11-bisethylnor-
spermine (BENSpm) which increases spermidine/sper-
mine N1-acetyltransferase (SSAT) activity resulting in a
higher acetylated polyamine export. At the same time,
cells are treated with a small molecule inhibitor (MTDIA)
of methylthioadenosine phosphorylase (MTAP), the key
enzyme in the methionine salvage pathway (MSP), which
is necessary for the cell to alleviate this stress, ultimately
leading to cell death. This approach was shown to be
effective in different prostate cancer cell models in vivo
and in vitro [89].
Androgen receptor signaling leads to increased prolifera-
tion and survival of prostate cancer cells. This is why
androgen deprivation therapy (ADT) is one of the main
treatment options for metastatic prostate cancer or upon
relapse to help control the spread of the disease. Andro-
gen receptor has also been shown to play a central role in
metabolic reprograming of prostate cancer cells. Andro-
gen receptor signaling upregulates the expression of
Dynamin related protein 1 (DRP1) in the mitochondria,
leading to increased pyruvate transport into the mito-
chondria and resulting in augmented OXPHOS and lipo-
genesis [90]. Moreover, high expression of DRP1 in
prostate cancer cells correlates with poor diseasewww.sciencedirect.com
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promotion of prostate cancer progression in connection to
androgen receptor (AR) signaling is Sirtuin7 (SIRT7)
[91]. SIRT7 depletion significantly reduces prostate
cancer cell proliferation and androgen-induced autophagy
in vitro and in vivo. Furthermore, upregulation of SIRT7
correlates with the expression of AR as well as prostate-
specific antigen (PSA) and could therefore be used as a
prognostic marker for prostate cancer in addition to being
a potential drug target.
T cell metabolism in prostate cancer
Hypoxia in prostate tumors has been associated with poor
prognosis [92]. T cells are largely excluded from hypoxic
zones within the tumor therefore drugs reversing hypoxia
represent a promising treatment strategy to increase T
cell infiltration and improve their fitness in the prostate
TME. In fact, hypoxia-activated prodrug TH-302 was
shown to eliminate hypoxia in the transgenic adenocarci-
noma of the mouse prostate (TRAMP) derived TRAMP-
C2 mouse model [93]. Additionally, treatment of
TRAMP-C2 mice with a combination of both TH-302
and immune checkpoint blockade (a-CTLA-4 and a-PD-
1) acts synergistically to cure over 80% of the tumors.
Indoleamine 2,3-dioxygenase (IDO) is the rate limiting
enzyme of the metabolic reaction in the metabolism of
tryptophan, which is known to be essential for T cell
activation. Excessive expression of IDO in cancer cells
leads to the depletion of tryptophan and the accumulation
of associated metabolites, which are known to inhibit T
cell expansion and activation as well as aid in the recruit-
ment of Treg cells and other suppressive cell types [94].
IDO expression was shown to correlate with higher stages
of prostate cancer progression and was indicative of
resistance to immunotherapy [95]. Furthermore, IDO
expression is higher after anti-tumoral vaccine or
a-PD-1 treatment. Taken together these results suggest
that IDO expression could be a mechanism of resistance
to immunotherapy, therefore future research including
IDO inhibitors in combination with immunotherapy
should be explored. Considering that IDO inhibition
has previously been studied as a potential addition to
immunotherapy in different cancer types without much
success [96], it is perhaps worth exploring therapeutic
effect of IDO inhibition in combination with different
types of therapies, potentially other metabolic targets in
addition to immunotherapy.
Several clinical trials are exploring the possibility of
immunotherapy for the treatment of prostate cancer.
The first cancer vaccine for the treatment of metastatic
castrate resistant prostate cancer was approved by the
FDA in 2010 and has been shown to prolong overall
survival by an average of 4 months [97]. Numerous other
cancer vaccines and different immunotherapeutic
approaches have been tested but ultimately none havewww.sciencedirect.com led to a dramatic improvement in prognosis for patients
with advanced prostate cancer [98]. Therefore, research
into new and improved therapeutic options are urgently
needed. Metabolic targets in both cancer and immune
cells represent a promising avenue to explore.
Conclusion
The idea of targeting metabolism in cancer therapy has
been around for a long time. In fact, many standard
chemotherapy drugs have metabolic targets. However,
systemic administration of many of these metabolic drugs
come with significant off target toxicity since they target
pathways that all healthy and cancer cells require for
proliferation (such as nucleotide synthesis). Over the past
decade immunotherapy has established itself as a prom-
ising treatment option for cancer patients. However, it has
become clear that on its own, immunotherapy in the form
of ICI and ACT is not successful for most patients. The
major limitation of these approaches is the fact that T cell
(and other anti-tumor immune cell) fitness is generally
compromised within the harsh TME. Moreover, the
ability of immunotherapy to unleash the immune system
against the tumor comes with the draw back to elicit
systemic immune reactions. For example, patients trea-
ted with ICI may experience colitis, hepatitis, myocardi-
tis, pneumonitis or neurotoxic effects all due to the
excessively activated immune system [99]. In an esti-
mated 0.3–1.3% of cases these complications can be fatal.
Cancer cells deplete crucial nutrients from the TME and
secrete factors that actively inhibit effector T cell func-
tion. As discussed in this review, the metabolic features of
the TME can vary significantly between the different
tissues of origin and even between cancer subtypes within
the same tissue. Consequently, T cell response in differ-
ent cancers differs as well due to the diverse adaptation of
T cells and their fitness within the specific TME. Target-
ing specific metabolic factors, in cancer cells and/or T
cells, based on the cancer tissue of origin and histotype
represents a promising treatment option to complement
immunotherapy. There are several approaches to con-
sider in this respect. Metabolic drugs could be used in
combination with immunotherapy as an ex vivo precon-
ditioning approach in order to induce T cell metabolic
adaptation to the specific TME and increase their infil-
tration and fitness which in turn would lead to improved
therapeutic efficiency of ACT. By treating TILs or engi-
neered T cells ex vivo before ACT, off target toxicity
related to metabolic reprograming could be avoided.
Alternatively, drugs targeting metabolism could be used
as part of the systemic immunotherapeutic regimen,
where patients would only need to be treated for a short
period of time, allowing the rewiring of the TME, there-
fore creating an opportunity for T cells, re-invigorated
through an immunotherapeutic approach, to enter the
TME and act against cancer cells. This would allow for a
more tissue specific response, possibly preventing
adverse reactions related to the systemic ‘re-activation’Current Opinion in Biotechnology 2021, 68:124–143
140 Systems biologyof the immune system. Mirroring this line of thinking, if
in cancer targeting metabolism holds the potential to
increase T cell fitness and to inhibit Treg cell suppressive
capacities, in case of autoimmune disorders dampening
the metabolic demands of reactive CD8+ T cells or
reinforcing the fitness of Treg cells can disclose new
strategies in the cure of this type of diseases.
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